04351PAD3
Ascendis Pharma A/s
Could not find a ticker for this position, may be a filing error
A Danish biopharmaceutical company that builds long-acting versions of existing medicines using its TransCon (transient conjugation) platform, which links a drug to a carrier molecule so it releases slowly in the body. Its approved products include Skytrofa for growth hormone deficiency and Yorvipath for hypoparathyroidism. Founded in Copenhagen in 2007 by entrepreneur Jan Møller Mikkelsen, the company takes its name from the Latin "ascendere," meaning "to climb."
CONVERTIBLEUnderlying: ASNDCUSIP: 04351PAD3HealthcareDK1 derivative reporter
2.25% Convertible Senior Notes due 2028
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
